Key PointsPfizer's free cash flow should improve.The drugmaker's lower leverage ratio target gives it greater financial flexibility.New products should cushion the blow from Pfizer's looming patent ...

Pfizer’s second quarter results were well received by the market, as the company outperformed Wall Street’s expectations for ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with ...